The first domestically produced integrated CoreVascu artificial blood vessel in the Greater Bay Area has started enrollment.

According to the news from Sanxin Medical, recently, the first domestically produced integrated CoreVascu artificial blood vessel clinical trial was officially launched at the Interventional Vascular Surgery Department of Shenzhen University Affiliated South Hospital, and the first implantation was efficiently completed by implementing the "launch and enrollment" strategy. The first enrollment in our center marks the official entry of CoreVascu artificial blood vessels into a new clinical stage in the Guangdong-Hong Kong-Macao Greater Bay Area. CoreVascu artificial blood vessels, jointly developed by Sanxin Medical and Zhejiang University of Technology, have successfully broken the long-term technological monopoly of foreign companies in the field of small-diameter artificial blood vessels.